Cullen/Frost Bankers, Inc.
BankPosition in RIGL — Rigel Pharmaceuticals Inc
CIK 39263
San Antonio, TX
Position in RIGL
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$2,893
-$52,015 QoQ
Shares Held
107
-91.7% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RIGL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cullen/Frost Bankers, Inc. holds $19,437,519 across 25 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
18,291 | $9,085,688 | |
| 2 | INSM |
INSMED Inc
|
54,740 | $5,836,378 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
10,977 | $3,304,406 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,028 | $640,999 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
3,868 | $136,888 | |
| 6 | EXEL |
Exelixis, Inc.
|
2,148 | $116,872 | |
| 7 | RPRX |
Royalty Pharma plc
|
2,016 | $113,037 | |
| 8 | ARGX |
Argenx SE
|
74 | $68,654 |
All Filings in RIGL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,893 | 107 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $54,908 | 1,282 | Shares | Defined | 2026-02-06 | |
| 2025-09-30 | $35,072 | 1,238 | Shares | Defined | 2025-10-31 | |
| 2025-06-30 | $24,873 | 1,328 | Shares | Defined | 2025-07-30 | |
| 2025-03-31 | $8,563 | 476 | Shares | Defined | 2025-05-02 | |
| 2024-12-31 | $6,761 | 402 | Shares | Defined | 2025-02-06 | |
| 2024-06-30 | $0 | 0 | Shares | Defined | 2024-08-05 | |
| No filing history on record for this holder in this stock. | ||||||